DK2430002T3 - FREMGANGSMÅDE TIL FREMSTILLING AF EN FORBINDELSE, DER ER ANVENDELIG SOM EN INHIBITOR AF TAFla - Google Patents

FREMGANGSMÅDE TIL FREMSTILLING AF EN FORBINDELSE, DER ER ANVENDELIG SOM EN INHIBITOR AF TAFla

Info

Publication number
DK2430002T3
DK2430002T3 DK10721758.0T DK10721758T DK2430002T3 DK 2430002 T3 DK2430002 T3 DK 2430002T3 DK 10721758 T DK10721758 T DK 10721758T DK 2430002 T3 DK2430002 T3 DK 2430002T3
Authority
DK
Denmark
Prior art keywords
tafla
inhibitor
preparing
procedure
relationship used
Prior art date
Application number
DK10721758.0T
Other languages
English (en)
Inventor
Kai Rossen
Volker Kraft
Hermut Wehlan
Antony Bigot
Veronique Crocq-Stuerga
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK2430002T3 publication Critical patent/DK2430002T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
DK10721758.0T 2009-05-15 2010-05-11 FREMGANGSMÅDE TIL FREMSTILLING AF EN FORBINDELSE, DER ER ANVENDELIG SOM EN INHIBITOR AF TAFla DK2430002T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290366 2009-05-15
PCT/EP2010/056426 WO2010130718A1 (en) 2009-05-15 2010-05-11 Process for the preparation of a compound useful as an inhibitor of tafia

Publications (1)

Publication Number Publication Date
DK2430002T3 true DK2430002T3 (da) 2013-11-04

Family

ID=41259362

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10721758.0T DK2430002T3 (da) 2009-05-15 2010-05-11 FREMGANGSMÅDE TIL FREMSTILLING AF EN FORBINDELSE, DER ER ANVENDELIG SOM EN INHIBITOR AF TAFla

Country Status (23)

Country Link
US (1) US8865906B2 (da)
EP (1) EP2430002B1 (da)
JP (1) JP5706397B2 (da)
KR (1) KR20120016651A (da)
CN (1) CN102459192B (da)
AU (1) AU2010247431B2 (da)
BR (1) BRPI1010571A2 (da)
CA (1) CA2760748A1 (da)
CY (1) CY1114493T1 (da)
DK (1) DK2430002T3 (da)
ES (1) ES2431068T3 (da)
HK (1) HK1168102A1 (da)
HR (1) HRP20130881T1 (da)
IL (1) IL216202A (da)
MX (1) MX2011011849A (da)
MY (1) MY157304A (da)
PL (1) PL2430002T3 (da)
PT (1) PT2430002E (da)
RS (1) RS52963B (da)
RU (1) RU2538506C2 (da)
SG (1) SG176558A1 (da)
SI (1) SI2430002T1 (da)
WO (1) WO2010130718A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX358628B (es) * 2010-03-18 2018-08-28 Daiichi Sankyo Co Ltd Derivado de imidazol sustituido con cicloalquilo.
JP5778133B2 (ja) * 2010-03-18 2015-09-16 第一三共株式会社 シクロプロパンカルボン酸誘導体
CN103201269A (zh) * 2010-11-11 2013-07-10 赛诺菲 3-(6-氨基-吡啶-3基)-2-丙烯酸衍生物的制备方法
WO2013076178A1 (en) 2011-11-25 2013-05-30 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP2782576B1 (en) 2011-11-25 2016-05-18 Sanofi Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
DK3589606T3 (da) * 2017-03-01 2024-01-02 Boehringer Ingelheim Int Overgangsmetal-katalyseret protodecarboxylering af alfa-halo-akrylsyrederivater

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4216218A (en) * 1979-02-23 1980-08-05 American Hoechst Corporation Antidepressant and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines
IT1177017B (it) * 1984-10-22 1987-08-26 Ravizza Spa Processo per la preparazione dell'acido 2(4-flurofenil)alfa-metil-5-benzox azoloacetico
FR2693192B1 (fr) * 1992-07-02 1994-08-12 Rhone Poulenc Agrochimie Dérivés de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
KR20010094731A (ko) * 1998-12-24 2001-11-01 후지야마 아키라 이미다졸 화합물 및 그의 의약 용도
US8710232B2 (en) 2004-04-22 2014-04-29 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives used as TAFIa inhibitors
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla

Also Published As

Publication number Publication date
US8865906B2 (en) 2014-10-21
PL2430002T3 (pl) 2013-12-31
KR20120016651A (ko) 2012-02-24
HK1168102A1 (en) 2012-12-21
AU2010247431A1 (en) 2011-12-01
JP5706397B2 (ja) 2015-04-22
SG176558A1 (en) 2012-01-30
CA2760748A1 (en) 2010-11-18
PT2430002E (pt) 2013-09-11
IL216202A (en) 2015-07-30
IL216202A0 (en) 2012-01-31
RU2011151044A (ru) 2013-06-20
RS52963B (en) 2014-02-28
MY157304A (en) 2016-05-31
SI2430002T1 (sl) 2013-10-30
EP2430002A1 (en) 2012-03-21
RU2538506C2 (ru) 2015-01-10
WO2010130718A1 (en) 2010-11-18
CY1114493T1 (el) 2016-10-05
HRP20130881T1 (hr) 2013-10-25
CN102459192A (zh) 2012-05-16
MX2011011849A (es) 2011-12-08
US20120245358A1 (en) 2012-09-27
JP2012526763A (ja) 2012-11-01
EP2430002B1 (en) 2013-07-24
BRPI1010571A2 (pt) 2019-09-24
CN102459192B (zh) 2015-06-24
ES2431068T3 (es) 2013-11-25
AU2010247431B2 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
DK2791134T3 (da) Kemisk forbindelse, der er anvendelig som mellemprodukt til fremstilling af en catechol-o-methyltransferasehæmmer
DK2310382T3 (da) Amidophenoxyindazoler, der er anvendelige som hæmmere af c-met
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
DK2662352T3 (da) Fremgangsmåde til fremstilling af phenylacetamidforbindelse
DK2470546T3 (da) HEXAHYDROOXAZINOPTERIDIN- forbindelser til anvendelse som mTOR INHIBITORER
DK2346888T3 (da) Fremgangsmåde til fremstilling af som SGLT-inhibitorer anvendelige forbindelser
DK2746265T3 (da) Heterocyclisk derivat som mikrosomal prostaglandin-E-syntase-(mPGEs)-inhibitor
DK2693881T3 (da) Substituerede n-phenylpyrimidin-2-amin-analoger som inhibitorer af axl-kinase
DK2467204T3 (da) Fremgangsmåde til fremstilling af en sorbent
DK2496562T3 (da) Fremgangsmåde til fremstilling af calcobutrol
DK3406337T3 (da) Fremgangsmåde til fremstilling af en hydrokrakningskatalysator
DK3511330T3 (da) Syntetisk mellemprodukt, der er anvendeligt til fremstilling af triazolopyridin-c-met-inhibitorer
DK2406253T3 (da) Benzofuranylderivater anvendt som glucokinase-inhibitorer
DK2491037T3 (da) Quinazolin-4(3h)-onderivater, der anvendes som pi3-kinase-inhibitorer
DK2691079T3 (da) Bionedbrydelige sammensætninger, der er egnet til kontrolleret udløsning
DK2242750T3 (da) Konformationelt begrænsede biphenyl-derivater til anvendelse som hepatitis C-virusinhibitorer
DK2475657T3 (da) 5-Alkynylthien-2-ylcarboxylsyrer som inhibitorer af flaviviridae-vira
DK2429486T3 (da) Fremgangsmåde til fremstilling af en tværbundet gel
DK2204453T3 (da) Fremgangsmåde til celle-fri fremstilling af kemikalier
DK2411397T3 (da) Isothiazol-pyrimidindionderivater som modulatorer af TRPA1
DK2526425T3 (da) Fremgangsmåde til diagnosticering af endometriel receptivitet
DK2595948T3 (da) Fremgangsmåde til fremstilling af ingenol-3-angelat
DK2421819T3 (da) Fremgangsmåde til iodering af aromatiske forbindelser
DK2424959T3 (da) Fremgangsmåde til fremstilling af en hydrokrakningskatalysator
DK2430002T3 (da) FREMGANGSMÅDE TIL FREMSTILLING AF EN FORBINDELSE, DER ER ANVENDELIG SOM EN INHIBITOR AF TAFla